19 results about "Oil Red O" patented technology

The invention relates to the technical field of biology, in particular to application of a GGPS1 activator, a pharmaceutical composition, a kit and a method. The invention relates to bone metabolism regulation and bone regeneration. It is found that improvement of GGPS1 expression / activity can activate TGF-beta / Smad2 / 3 by down-regulating LTBP1, so that human bone marrow mesenchymal stem cells are converted from adipogenesis to osteogenesis, and bone formation and bone defect repair are promoted. The invention provides a drug containing a GGPS1 activator and a controlled release composition for implantation, which are used for osteoporosis, bone mass reduction, delayed fracture healing and the like. The invention also provides an in-vitro screening and evaluation method and a detection kit, and the indexes such as p-Smad2 / 3, alizarin red, oil red O and the like are used for judgment. The invention realizes upstream heavy balance and has the advantages of bone promotion and fat suppression.

The invention belongs to the technical field of biology, and particularly relates to an oil red O modified coupling coloring agent and a frozen section dyeing method thereof. The oil red O modified coupling coloring agent comprises a carboxylated oil red O stock solution, a coupling agent, a buffer solution and Triton X-100, the carboxylated oil red O stock solution is modified through succinic anhydride, EDC and NHS, oil red O can be converted into a specific molecular dye from a hydrophobicity-dependent similar-dissolvable non-specific physical dye, lipid molecules are actively combined, and the specific molecular dye is converted into the specific molecular dye. And different types of lipid molecules are dyed, other cell structures are not adhered, and a non-specific background is eliminated, so that weak signals such as tiny lipid droplets, cell membrane lipid and the like can be clearly dyed and captured, and the imaging quality and the accuracy of quantitative analysis are improved.

The invention provides application of lncPRPD regulation and control on GLRX5 in improving pork quality, the lncPRPD is lncRNA obtained by performing whole transcriptome sequencing analysis on longissimus dorsi muscle of Laiwu pigs, and the nucleotide sequence of the lncPRPD is as shown in SEQ ID NO: 1. The method comprises the following steps: firstly, synthesizing a small interfering RNA (Ribonucleic Acid) of the lncPRPD / GLRX5 and constructing a gene overexpression vector of the lncPRPD / GLRX5; then, detecting the combination of the lncPRPD and the GLRX5 protein by utilizing a Pulldown experiment and a Western blot experiment; the expression quantity of the GLRX5 is detected after interference and overexpression of the lncPRPD, and it is found that the lncPRPD can promote expression of the GLRX5 protein level; through detection experiments such as qPCR (quantitative polymerase chain reaction), Western blot, oil red O staining and the like, the lncPRPD and the GLRX5 are detected to be capable of promoting the differentiation of the pig precursor fat cells.

The invention discloses a fermentation method for fungus-enzyme synergistic treatment of lucid ganoderma and application of the method in pet food. The fermentation method comprises the following steps: (1) enzymolysis pretreatment: mixing ganoderma lucidum sporocarp powder with water, adding cellulase and laccase, and performing enzymolysis to obtain an enzymolysis solution; (2) sterilizing and supplementing a carbon source: adding the carbon source into the enzymatic hydrolysate, and sterilizing; (3) lactobacillus fermentation: adding lactobacillus plantarum into the sterilized enzymatic hydrolysate, and fermenting under a fermentation condition to obtain fermentation liquor; and (4) solid-liquid separation: performing centrifugal separation on the fermentation liquor, and collecting supernate to obtain the ganoderma lucidum fermentation liquor. According to the method, the laccase and the cellulase are synergistically broken, so that the release efficiency of triterpenes and total phenols in the ganoderma lucidum with spores is remarkably improved. The fermentation liquor can improve lipid accumulation (the oil red O staining lipid content is reduced) and relieve oxidative stress injury on the cell level, and can be used for preparing functional food for improving metabolic health, especially for lipid abnormality and oxidative stress state related to metabolic dysfunction of pets.

The invention discloses application of human dental pulp stem cells in enhancing neurogenesis in a brain region and treating neurodegenerative diseases, including stem cells for enhancing neurogenesis of adult hippocampus, and the human dental pulp stem cells have the following functional characteristics: flow cytometry detection shows that the Netin positive rate is not lower than 90%, and the beta-tubulin III positive rate is not lower than 85%; in a conditioned culture medium after in-vitro culture for 24 hours, the secretion amount of BDNF reaches more than 500pg / mL / 106 cells, and the secretion amount of GDNF reaches more than 200pg / mL / 106 cells; the alizarin red dyeing positive area accounts for not less than 60% after osteogenesis induction, and the oil red O dyeing positive area accounts for not less than 50% after adipogenesis induction; according to the quantitative standard that the number of dentate gyrus DCX + newborn neurons of the adult hippocampus is increased by more than 50% compared with that before treatment, the dual-mechanism targeted therapy 1 specifically activates hippocampus neural stem cells and promotes newborn neurons to differentiate by highly expressing neural markers and secreting neurotrophic factors, so that the neurogenesis of the adult hippocampus is enhanced, and the neurogenesis of the adult hippocampus is enhanced. Meanwhile, A beta deposition and p-Tau phosphorylation are reduced.

The invention discloses application of physcion in preparation of a medicine for reducing liver cell lipid deposition, and particularly relates to application of physcion in preparation of a medicine for preventing and treating lipid deposition fatty liver. In-vitro cell experiments prove that the physcion shows low toxicity and a wide safety range in a human normal hepatocyte line THLE3, a human hepatoma cell line HepG2 and a mouse normal hepatocyte line AML12, and can obviously reduce the level of oleic acid-induced intracellular triglyceride in a dose-dependent manner, so that the physcion can be used for preparing a medicine for treating liver cancer. Oil red O staining results also visually show that lipid droplet accumulation in cells can be effectively reduced; according to the invention, the technical prejudice that the emodin monomethyl ether is regarded as a potential hepatotoxic component in the prior art is overcome, a safe and effective new choice is provided for the treatment of the lipid deposition fatty liver, and the pharmaceutical composition has a wide clinical application prospect.

This invention discloses a method for evaluating the bioavailability of soybean oil based on an in vitro digestion / cell co-culture model. Soybean oil is emulsified using WPI emulsifier and then digested sequentially through simulated gastric and intestinal fluids to obtain the gastric digestion products of soybean oil. Fatty acids are extracted from the intestinal digestion products of soybean oil, dissolved in dimethyl sulfoxide, and linked to fatty acid-free bovine serum albumin to obtain in vitro digestion products of soybean oil that can be absorbed by the intestines. These are then added to a cell co-culture model for cell incubation and transport. HepG2 cells from the cell co-culture model are collected, and Oil Red O staining and total triglyceride content are measured to obtain lipid deposition, thereby evaluating the bioavailability of soybean oil. The in vitro digestion / cell co-culture model of this invention is specifically designed for soybean oil digestion. This method objectively and scientifically evaluates the bioavailability of soybean oil at different metabolic stages, providing a standard basis for the scientific and healthy consumption of soybean oil and possessing significant practical value.

The invention relates to application of an HAX1 agonist in serving as a medicine for improving osteogenesis and mineralization capacity of periodontal ligament stem cells and preparing a medicine for treating periodontitis, and belongs to the technical field of biomedical engineering. HAX1 overexpression and knock-down periodontal ligament stem cell lines are successfully constructed, and then adipogenesis, osteogenesis and mineralization induction are conducted on the HAX1 overexpression and knock-down periodontal ligament stem cell lines. The adipogenic differentiation is evaluated through oil red O staining, the osteogenic differentiation is evaluated through alkaline phosphatase (ALP) staining, the mineralization ability is determined through alizarin red staining, and the proliferation activity is determined through a CCK-8 experiment; rT-qPCR (real-time quantitative polymerase chain reaction) and Western blot are adopted to analyze and quantify mRNA (messenger ribonucleic acid) and protein expression of genes related to the RAF / MEK / ERK signal channel, and the effectiveness of HAX1 operation is verified. The result shows that overexpression of the HAX1 enhances the osteogenic differentiation and mineralization capabilities of the periodontal ligament stem cells, and the reverse effect is generated after the HAX1 is knocked down. Analysis on an RAF / MEK / ERK signal pathway shows that HAX1 overexpression significantly promotes MEK / ERK phosphorylation and pathway activation, but does not affect an RAF family.

The present invention relates to a lipid-lowering peptide and its use. The lipid-lowering peptide has the sequence: NAIIGPRW, and can reduce the levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol, while also increasing the level of high-density lipoprotein cholesterol. Oil Red O staining experiments have shown that the lipid-lowering peptide of the present invention can effectively inhibit preadipocyte differentiation and has the ability to inhibit pancreatic lipase activity. Toxicity experiments have shown that the lipid-lowering peptide of the present invention is also highly safe.

The present invention discloses an Oil Red O staining solution composed of 0.5% Oil Red O, 50% ethanol, and 5%-10% salicylic acid. The staining solution does not contain any toxic organic solvents, is non-toxic, and has good safety. The present invention also discloses a method for staining cells or tissues with Oil Red O. The method has the advantages of simple operation, short staining time, easy staining of neutral fats in cells or tissues, good staining effect, and a clean background. The method does not use isopropyl alcohol, is safe and convenient, and is suitable for promotion and application in various laboratories.

The invention discloses a classification method for verifying burden-reducing and transsaccharide hypoglycemic drugs, and belongs to the technical field of drug relationship classification, male mice are selected, are freely fed with common feed and then are replaced with high-fat feed, STZ injection is carried out, then the mice are selected and grouped, and the drug administration volume is adjusted according to the body weight; metabolism cage detection, OGTT / IRT and dynamic blood glucose detection are carried out alternately; carrying out sample collection according to a sequence of heart, kidney, liver, quadriceps femoris muscle, aorta and pancreas; establishing a database for data analysis; detecting a tissue morphological structure, a kidney SGLT2 protein expression quantity, a liver glycogen content and muscle GLUT4 membrane translocation efficiency; detecting the sensitivity of serum beta-hydroxybutyric acid (ketone body) and insulin; and pathological analysis is carried out through aorta oil red O and pancreas beta cell morphological staining. According to the method, a'burden-reducing type-transsaccharide 'classification standard based on a physiological mechanism is created for the first time, the problem that traditional chemical structure / target point classification is disjointed with drug effects is solved, and the classification accuracy reaches 92.3% (n is equal to 60 animal verification).

The invention discloses a dynamic detection method for mouse liver organoid response lipid, and belongs to the technical field of biological research. Culturing the liver-like organs of the mouse to a preset number of days; randomly dividing the organs into at least three groups, and respectively treating by using a complete culture medium, a culture medium containing free fatty acid and a culture medium containing cholesterol; after the treatment is finished, sequentially carrying out bright field imaging and oil red O dyeing imaging on the same batch of organ-like samples; organ-like morphological parameters obtained by bright field images and the overall accumulation condition of neutral lipid disclosed by oil red O staining images are integrated and analyzed, and the cell growth condition of mouse liver organ-like cells and histological morphological change of the organ-like are evaluated by HE staining. Therefore, multi-dimensional and visual distinguishing and quantitative evaluation of lipid metabolism response induced by fatty acid and cholesterol are realized. According to the method, form-phenotype-molecule comprehensive evaluation is realized, and the problems that in the prior art, the information dimension is limited, and different lipid responses cannot be accurately distinguished are solved.

The invention discloses a pharmaceutical composition for treating non-alcoholic fatty liver as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The invention discloses a pharmaceutical composition for treating non-alcoholic fatty liver disease. The pharmaceutical composition is prepared from a curdione / beta-cyclodextrin inclusion compound, glutaraldehyde cross-linked ganoderma lucidum polysaccharide and salidroside. According to the pharmaceutical composition developed by the invention, through the synergistic effect of curdione, ganoderan and salidroside, lipid metabolism disorder of a non-alcoholic fatty liver model is remarkably improved, liver cell injury is relieved, HE staining and oil red O staining prove that the pharmaceutical composition can reduce intrahepatic fat vacuoles and repair liver tissue structures, the effect of a medium dose group is optimal, and the effect of a low dose group is excellent. The effect is obviously better than that of each single component which is independently used, and a safe and efficient treatment scheme is provided for the non-alcoholic fatty liver disease.

The invention discloses an application of dehydrocorydaline or a pharmaceutically acceptable salt thereof in preparation of a product for preventing and / or treating atherosclerosis and related diseases thereof. The application is verified by animal experiments based on an ApoE- / -mouse model, and results of general aorta Oil Red O staining, aortic sinus HE / Oil Red O staining, serum inflammatory factor ELISA and the like of the inventor prove that the dehydrocorydaline has remarkable morphological improvement and inflammation regulation effects on atherosclerosis. It is found for the first time that the dehydrocorydaline can be used for preparing the medicine for preventing or treating the atherosclerosis and related cardiovascular events of the atherosclerosis, and therefore a new safe and effective multi-target treatment way is provided for comprehensive intervention of the atherosclerosis.

The application discloses a new application of mulberry polysaccharide in preparation of a medicine for treating type 2 diabetes by regulating intestinal flora, and belongs to the technical field of medicinal and edible plant polysaccharides. In the application, a type 2 diabetes rat model is constructed by using high-sugar and high-fat feed in combination with streptozotocin, biochemical index detection, liver HE staining and oil red O staining, intestinal flora 16S rRNA high-throughput sequencing, and GC-MS detection of short-chain fatty acid content are carried out, so as to confirm that the mulberry polysaccharide can regulate the intestinal flora structure of T2DM rats, improve the secretion level of short-chain fatty acids, improve insulin resistance and glycolipid metabolism disorder, enhance the antioxidant capacity of the body, and repair the pathological damage of the liver. The application clearly defines the anti-type 2 diabetes mechanism of the mulberry polysaccharide, which takes the intestinal flora-short-chain fatty acid axis as the core. The mulberry polysaccharide is a natural low-toxicity medicinal and edible active ingredient, has no side effects of chemical hypoglycemic drugs, can be prepared into various oral medicine dosage forms, and is used for the prevention and clinical treatment of type 2 diabetes, so the application prospect is wide.

The invention discloses a preparation method and application of a near-infrared fluorescent probe for specifically recognizing foam cells, and relates to the technical field of fluorescent probes. The probe adopts an electron donor-conjugated olefinic bond-electron acceptor (D-pi-A) molecular architecture, the lipid binding capacity is enhanced through a dihexylaminobenzene unit, 705nm near-infrared emission is realized through a pyridinium group, and the membrane binding stability is improved by combining with a double positive charge group. The probe has the characteristics of no washing and rapid marking, living cell imaging can be completed within 5 minutes, the fluorescence intensity is enhanced by 42.5 times in a lipid environment, and foam cells and normal macrophages can be specifically distinguished. Compared with a traditional oil red O staining technology, the method has the advantages that real-time dynamic monitoring of the foam cell generation process is realized in a breakthrough manner, and a novel molecular tool is provided for atherosclerosis early pathological mechanism research, drug curative effect evaluation and clinical diagnosis.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a metabolism-related fatty liver disease animal model. According to the invention, AAV-ASIC1a-shRNA virus is injected into a PVN brain region of a target animal, ASIC1a channel protein is knocked down, the weight and liver weight of the target animal are increased, the triglyceride level of serum is increased, and Hamp is used as an antigen; e staining prompts that hepatocytes are obviously swollen, cell nucleuses are deviated and even disappear, the hepatocytes have obvious inflammatory change, oil red O staining lipid is obviously increased, all the characteristics reproduce clinical and existing laboratory mouse characteristics of MAFLD, and the standards of MAFLD animal models are met.

The invention discloses a pig intramuscular adipose cells (AMSCs) and pig skeletal muscle satellite cells (PSCs) co-culture system establishment method, which comprises the steps of cell separation and identification, co-culture medium preparation, co-culture operation and effect identification, and specifically comprises the following steps: step 1, cell separation and identification, step 2, co-culture medium preparation, and step 3, co-culture operation. 4, effect identification: grease formation of AMSCs is identified through oil red O staining, muscle formation of PSCs is identified through immunofluorescence staining, and the grease formation rate and the muscle formation rate are both larger than or equal to 85%. The special culture medium can meet the nutritional requirements of two cells at the same time, and the inhibition of a single culture medium on the growth or differentiation of a certain type of cells is avoided. By synchronously inducing directional differentiation of two cells, obvious myotubular structures and lipid droplets are finally formed, and the differentiation effect is stable and repeatable. And an ideal model is provided for exploring a collaborative regulation molecular mechanism of intramuscular fat deposition and muscle growth.

The invention relates to a method for constructing a non-alcoholic steatohepatitis mouse model. The method sequentially comprises the following steps that SPF-level C57BL / 6 male mice are divided into a model group and a control group after a standard feed and drinking adaptive period for one week; the model group is fed with high-fat and high-cholesterol diet, sweet water is given, CCl4 injection is carried out once a week, and standard feed and drinking water are given to the control group; monitoring fasting weight every week; in the fourth week and the twelfth week, the mouse is killed, livers are collected and weighed, tissue slices are prepared, oil red O, sirius red and HE staining analysis is conducted, and then evaluation analysis is conducted. The method provided by the invention overcomes the limitation of the existing model, and also provides support for the research of NASH etiology and the development of new drugs.